Peter Kim - Articles and news items

Merck logo

VICTRELIS® (boceprevir) awarded 2012 Prix Galien USA Best Pharmaceutical Agent

Industry news, News / 17 October 2012 / Merck

VICTRELIS® has received the Prix Galien USA Award for best pharmaceutical agent

Merck logo

Update on Phase III trial for Odanacatib, Merck’s investigational cat-K inhibitor for Osteoporosis

Industry news, News / 11 July 2012 / Merck

Merck announced an update on the Phase III trial…

Phenomenex Logo

Phenomenex streamlines access to applications library with unique structure search capability

News, Supplier news / 31 May 2012 / Phenomenex

Phenomenex Inc., announces unique new Structure Search functionality…

Merck logo

Exclusive worldwide agreement to develop and commercialize Phase III cancer candidate vintafolide (EC145)

Industry news, News / 16 April 2012 / Merck

Vintafolide is currently being evaluated in a Phase III clinical trial…

Merck logo

Merck announces top-line results of TRA-2P study of Vorapaxar

Industry news, News / 7 February 2012 / Merck

Company will review data from TRA-2P and TRACER with external experts to inform next steps…

Merck logo

Merck provides update on development program for Suvorexant

Industry news, News / 6 February 2012 / Merck

Company Confirms Plans to File NDA for Suvorexant in 2012…

Merck logo

Merck establishes new MSD R&D Asia Headquarters

Industry news, News / 6 December 2011 /

Commits $1.5 billion to R&D in China over the next 5 years…

Merck logo
Merck logo

CHMP issues positive opinion for Merck’s VICTRELIS™ (boceprevir)

Industry news, News / 20 May 2011 / Merck

Merck announced that the CHMP of the EMA has adopted a positive opinion under accelerated assessment recommending approval of the investigational medicine VICTRELIS™…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...